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The malaria vaccine candidate GMZ2 is a recombinant
fusion protein of Plasmodium falciparum Glutamate
Rich Protein and Merozoite Surface Protein 3, adju-
vanted with aluminium hydroxide. Trials in malaria
naive adults in Germany and in Gabon in adults
exposed to malaria and subsequently in children 1-5yrs
showed that three doses of 100ug GMZ2 are well toler-
ated and immunogenic. The aim of this phase 2b trial is
to determine whether the GZ2 vaccine can protect
against clinical attacks of malaria in children aged
1-5yrs, to obtain more extensive data on safety, toler-
ability and immunogenicity, and to determine if the vac-
cine can prevent anaemia and reduce the parasite
density and gametocyte carriage.
The primary endpoint is the incidence of clinical
m a l a r i ad e f i n e da sf e v e ro rh i s t o r yo ff e v e ri nt h ep r e -
vious 24 hours with parasite density of 5000 asexual
parasites per ul or more, detected by passive surveillance
over a 6 month period from the third vaccination. All
malaria episodes will be included in the calculation of
vaccine efficacy. This endpoint is chosen in order to
have the optimum power to detect a protective effect;
efficacy will also be calculated using a range of different
parasite density cutoff values. Children will be followed
for a total of 22 months from the third vaccination.
Immune responses to the vaccine antigens GMZ2,
GLURP and MSP3 will be assessed by measuring anti-
gen specific IgG by ELISA, and antigen specific memory
B-cell responses by ELISPOT. Functionality of the
immune response will be assessed by growth inhibition
of P. falciparum in the presence or absence of mono-
cytes. Cell mediated immunogenicity will be assessed by
cytokine profiling and intracellular cell staining follow-
ing stimulation with the vaccine antigen, and the quality
o ft h ea n t i b o d yr e s p o n s eb yt y p ea n ds u b c l a s s - s p e c i f i c
ELISA.
The planning of the trial was complicated by the need
to take account of the changing epidemiology of
malaria. Baseline studies were conducted in five poten-
tial trial sites to determine the current incidence of
malaria; in each site two cohorts of children were
followed to estimate the incidence of malaria by active
and passive surveillance and by passive surveillance
alone. Four sites with higher malaria incidence were
chosen for recruitment. A total sample size of 1840 will
be enrolled in each of the four sites in 2010/11.
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